253 related articles for article (PubMed ID: 25348528)
21. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ
J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
[TBL] [Abstract][Full Text] [Related]
22. Time kill-assays of antibiotic combinations for multidrug resistant clinical isolates of OXA-48 carbapenemase producing Klebsiella pneumoniae.
Erdem F; Díez-Aguilar M; Oksuz L; Kayacan C; Abulaila A; Oncul O; Morosini MI; Cantón R; Aktas Z
Acta Microbiol Immunol Hung; 2022 Sep; 69(3):215-219. PubMed ID: 35895557
[TBL] [Abstract][Full Text] [Related]
23. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
Landersdorfer CB; Rees VE; Yadav R; Rogers KE; Kim TH; Bergen PJ; Cheah SE; Boyce JD; Peleg AY; Oliver A; Shin BS; Nation RL; Bulitta JB
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437610
[TBL] [Abstract][Full Text] [Related]
24. [In vitro combination effects of doripenem with aminoglycoside or ciprofloxacin against Pseudomonas aeruginosa].
Anan N; Toba S; Ito A; Nakamura R; Tsuji M
Jpn J Antibiot; 2011 Aug; 64(4):203-16. PubMed ID: 22066345
[TBL] [Abstract][Full Text] [Related]
25. In vitro synergistic activity of colistin and ceftazidime or ciprofloxacin against multidrug-resistant clinical strains of Pseudomonas aeruginosa.
D'Souza BB; Padmaraj SR; Rekha PD; Tellis RC; Prabhu S; Pothen P
Microb Drug Resist; 2014 Dec; 20(6):550-4. PubMed ID: 25055029
[TBL] [Abstract][Full Text] [Related]
26. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.
Zhanel GG; Mayer M; Laing N; Adam HJ
Antimicrob Agents Chemother; 2006 Jun; 50(6):2228-30. PubMed ID: 16723591
[TBL] [Abstract][Full Text] [Related]
27. In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.
Dundar D; Otkun M
Yonsei Med J; 2010 Jan; 51(1):111-6. PubMed ID: 20046523
[TBL] [Abstract][Full Text] [Related]
28. Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments.
Tängdén T; Karvanen M; Friberg LE; Odenholt I; Cars O
Infect Dis (Lond); 2017 Jul; 49(7):521-527. PubMed ID: 28264618
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of meropenem extended infusion vs intermittent bolus monotherapy and in combination with colistin against Pseudomonas aeruginosa biofilm.
Benavent E; Ulldemolins M; El Haj C; Rigo-Bonnin R; Yu H; Wang L; Wickremasinghe H; Ariza J; Murillo O
Int J Antimicrob Agents; 2023 Aug; 62(2):106856. PubMed ID: 37211260
[TBL] [Abstract][Full Text] [Related]
30. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa.
Lang BJ; Aaron SD; Ferris W; Hebert PC; MacDonald NE
Am J Respir Crit Care Med; 2000 Dec; 162(6):2241-5. PubMed ID: 11112146
[TBL] [Abstract][Full Text] [Related]
31. Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant.
Drusano GL; Liu W; Fregeau C; Kulawy R; Louie A
Antimicrob Agents Chemother; 2009 Jun; 53(6):2266-73. PubMed ID: 19289521
[TBL] [Abstract][Full Text] [Related]
32. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa.
Chin JN; Jones RN; Sader HS; Savage PB; Rybak MJ
J Antimicrob Chemother; 2008 Feb; 61(2):365-70. PubMed ID: 18079128
[TBL] [Abstract][Full Text] [Related]
33. The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection.
Wang Y; Li C; Wang J; Bai N; Zhang H; Chi Y; Cai Y
Microbiol Spectr; 2022 Oct; 10(5):e0146822. PubMed ID: 36102678
[TBL] [Abstract][Full Text] [Related]
34. The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
Law JP; Wood AJ; Friman VP
Microbiol Spectr; 2022 Dec; 10(6):e0184222. PubMed ID: 36453898
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes.
Buyck JM; Tulkens PM; Van Bambeke F
Antimicrob Agents Chemother; 2013 May; 57(5):2310-8. PubMed ID: 23478951
[TBL] [Abstract][Full Text] [Related]
36. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.
Bonacorsi S; Fitoussi F; Lhopital S; Bingen E
Antimicrob Agents Chemother; 1999 Feb; 43(2):213-7. PubMed ID: 9925508
[TBL] [Abstract][Full Text] [Related]
37. RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria.
Buyck JM; Peyrusson F; Tulkens PM; Van Bambeke F
Antimicrob Agents Chemother; 2015 Aug; 59(8):4750-8. PubMed ID: 26014952
[TBL] [Abstract][Full Text] [Related]
38. In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
Bozkurt-Guzel C; Savage PB; Gerceker AA
Chemotherapy; 2011; 57(6):505-10. PubMed ID: 22286090
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
[TBL] [Abstract][Full Text] [Related]
40. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Hu YF; Liu CP; Wang NY; Shih SC
BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
